Crystal Structures of Malonyl-Coenzyme A Decarboxylase Provide Insights into Its Catalytic Mechanism and Disease-Causing Mutations by Froese, D. . et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal Structures of Malonyl-Coenzyme A Decarboxylase
Provide Insights into Its Catalytic Mechanism and Disease-
Causing Mutations
Citation for published version:
Froese, D, Vollmar, M, Puranik, S, Savitsky, P, Krojer, T, Pilka, E, Kiyani, W, Lee, W, Marsden, B, von Delft,
F, Allerston, C, Gileadi, O, Oppermann, U, Yue, W, Forouhar, F, Tran, T, Kim, Y, Lew, S, Neely, H,
Seetharaman, J, Shen, Y, Tong, L, Xiao, R, Acton, T, Everett, J, Montelione, G, Cannone, G & Spagnolo, L
2013, 'Crystal Structures of Malonyl-Coenzyme A Decarboxylase Provide Insights into Its Catalytic
Mechanism and Disease-Causing Mutations' Structure. DOI: 10.1016/j.str.2013.05.001
Digital Object Identifier (DOI):
10.1016/j.str.2013.05.001
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Structure
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Structure
Article
Crystal Structures of Malonyl-Coenzyme A
Decarboxylase Provide Insights into Its Catalytic
Mechanism and Disease-Causing Mutations
D. Sean Froese,1,7 Farhad Forouhar,2,7 Timothy H. Tran,2,7 Melanie Vollmar,1 Yi Seul Kim,2 Scott Lew,2 Helen Neely,2
Jayaraman Seetharaman,2 Yang Shen,2 Rong Xiao,3,4 Thomas B. Acton,3,4 John K. Everett,3,4 Giuseppe Cannone,5
Sriharsha Puranik,1 Pavel Savitsky,1 Tobias Krojer,1 Ewa S. Pilka,1 Wasim Kiyani,1 Wen Hwa Lee,1 Brian D. Marsden,1
Frank von Delft,1 Charles K. Allerston,1 Laura Spagnolo,5 Opher Gileadi,1 Gaetano T. Montelione,3,4 Udo Oppermann,1,6
Wyatt W. Yue,1,* and Liang Tong2,*
1Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK
2Department of Biological Sciences, Northeast Structural Genomics Consortium, Columbia University, New York, NY 10027, USA
3Center for Advanced Biotechnology and Medicine, Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway,
NJ 08854, USA
4Department of Biochemistry, Northeast Structural Genomics Consortium, Robert Wood Johnson Medical School, Piscataway,
NJ 08854, USA
5Institute of Structural Molecular Biology, University of Edinburgh, Edinburgh EH9 3JR, UK
6NIHR Oxford Biomedical Research Unit, Botnar Research Centre, Oxford OX3 7LD, UK
7These authors contributed equally to this work
*Correspondence: wyatt.yue@sgc.ox.ac.uk (W.W.Y.), ltong@columbia.edu (L.T.)
http://dx.doi.org/10.1016/j.str.2013.05.001
SUMMARY
Malonyl-coenzyme A decarboxylase (MCD) is found
from bacteria to humans, has important roles in
regulating fatty acid metabolism and food intake,
and is an attractive target for drug discovery. We
report here four crystal structures of MCD from hu-
man, Rhodopseudomonas palustris, Agrobacterium
vitis, and Cupriavidus metallidurans at up to 2.3 A˚
resolution. The MCD monomer contains an N-termi-
nal helical domain involved in oligomerization and a
C-terminal catalytic domain. The four structures
exhibit substantial differences in the organization of
the helical domains and, consequently, the oligo-
meric states and intersubunit interfaces. Unexpect-
edly, the MCD catalytic domain is structurally
homologous to those of the GCN5-related N-acetyl-
transferase superfamily, especially the curacin A pol-
yketide synthase catalytic module, with a conserved
His-Ser/Thr dyad important for catalysis. Our struc-
tures, along with mutagenesis and kinetic studies,
provide a molecular basis for understanding patho-
genic mutations and catalysis, as well as a template
for structure-based drug design.
INTRODUCTION
Malonyl-coenzyme A (malonyl-CoA) has long been established
as the key intermediate in the biosynthesis of long-chain and
very long-chain fatty acids (Wakil et al., 1983; Zammit, 1999),
and it also has a crucial role in the regulation of fatty acid oxida-
tion in mammals through its potent inhibition of carnitine palmi-
toyltransferase I (McGarry and Brown, 1997; Ramsay et al.,
2001). Recent studies have demonstrated other important
functions for this metabolite (Folmes and Lopaschuk, 2007; Lo-
paschuk et al., 2010; Saggerson, 2008), for example, in the regu-
lation of food intake through its actions in the central nervous
system (Fantino, 2011; Lane et al., 2008; Wolfgang and Lane,
2008) and in the control of fuel selection (carbohydrate versus
fatty acids) in many tissues (Folmes and Lopaschuk, 2007; Sag-
gerson, 2008). Therefore, malonyl-CoA may be a crucial regu-
lator of energy homeostasis.
Cellular malonyl-CoA levels are controlled by several en-
zymes. Malonyl-CoA is produced by acetyl-CoA carboxylase
(Cronan and Waldrop, 2002; Tong, 2013; Wakil et al., 1983)
and is consumed by fatty acid synthase (Kuhajda, 2006), elon-
gases (Guillou et al., 2010), and malonyl-CoA decarboxylase
(MCD, E.C. 4.1.1.9) (Saggerson, 2008). The functional impor-
tance of malonyl-CoA suggests that modulators of these
enzymes may have therapeutic applications. Hepatic overex-
pression of MCD in rats led to a decrease in circulating free fatty
acid and, more importantly, alleviated insulin resistance normally
induced by a high-fat diet (An et al., 2004). On the other hand, in-
hibition of MCD in the heart may be beneficial for treating cardiac
ischemia and reperfusion (Ussher and Lopaschuk, 2009), which
is supported by observations on MCD/ mice (Dyck et al.,
2006), as well as a collection of MCD inhibitors (Cheng et al.,
2006a, 2006b, 2006c; Wallace et al., 2007). MCD inhibition has
been found to be toxic to cancer cells, suggesting that it may
be a target for anticancer therapy (Zhou et al., 2009). MCD inhi-
bition can also reduce food intake and may be beneficial for
obesity and diabetes treatment (Lopaschuk et al., 2010; Tang
et al., 2010).
In mammals, MCD activity is found in the cytoplasm, mito-
chondria, and peroxisomes, and these different isoforms are en-
coded by a single gene (Courchesne-Smith et al., 1992; Gao
et al., 1999; Joly et al., 2005; Sacksteder et al., 1999). MCD
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deficiency in humans (Mendelian Inheritance in Man No.
248360), a rare autosomal recessive disorder, is characterized
by malonic aciduria, developmental delay, cardiomyopathy,
and neonatal death in severe cases (Malvagia et al., 2007; Salo-
mons et al., 2007; Xue et al., 2012), supporting the important role
of this enzyme in cellular functions. There is, as yet, no genotype-
phenotype correlation for the 30 pathogenic mutations identi-
fied (Xue et al., 2012).
MCD (50 kDa) is also found in bacteria, plants, and other or-
ganisms with conserved amino acid sequences (Figure 1). For
example, human MCD (HsMCD) and Rhodopseudomonas
palustris MCD (RpMCD) share 34% sequence identity, while
RpMCD and Rhizobium etliMCD (ReMCD) share 56% sequence
identity (Figure 1). MCDs belong to the PFAM domain family
PF05292 but do not share recognizable homology with other
proteins in the sequence database, including methylmalonyl-
CoA decarboxylase (Benning et al., 2000) and other decarboxy-
lases. Purification of several animal and bacterial MCDs have
been reported over the years (Kim and Kolattukudy, 1978; Kolat-
tukudy et al., 1981; Lee et al., 2002; Lo et al., 2008; Zhou et al.,
2004), and the crystallization of a bacterial MCD was also re-
ported (Jung et al., 2003). However, no crystal structure was
available on any of theMCDs, and the catalytic mechanism is still
poorly understood.
We report here the crystal structures of humanMCD as well as
three bacterial MCDs at up to 2.3 A˚ resolution. The MCD mono-
mer contains an N-terminal helical domain and a C-terminal cat-
alytic domain, and the catalytic domain shares unexpected
structural homology to the GCN5-related N-acetyltransferase
(GNAT) superfamily. The N-terminal helical domain is involved
in the oligomerization of MCDs, although there are substantial
differences in the organization of the dimers and tetramers
among MCD orthologs.
RESULTS AND DISCUSSION
Structure Determination
Wild-type HsMCD (residues 40–491, corresponding to the
maturemitochondrial form) failed to crystallize. Adopting the sur-
face entropy reduction (SER) strategy (Cooper et al., 2007), two
charged patches in HsMCD, Glu58-Lys59 and Glu278-Glu279-
Lys280, were predicted to be surface-exposed by the SER pre-
diction server (http://services.mbi.ucla.edu/SER/; Goldschmidt
et al., 2007), and site-directed mutagenesis was used to
Figure 1. Sequence Alignment of HsMCD, RpMCD, CmMCD, AvMCD, and ReMCD
The secondary structure elements for HsMCD are indicated at the top of the alignment, colored in yellow for those in the helical domain and cyan for those in the
catalytic domain. Strictly conserved residues among the five sequences are shown in red and highly conserved residues in blue. The purple diamonds indicate
sites of disease-causing missense mutations in HsMCD.
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substitute alanine for each of these residues simultaneously. The
structure of the E58A/K59A/E278A/E279A/K280A quintuple
mutant was determined by single isomorphous replacement
with anomalous scattering and refined at 2.8 A˚ resolution (Table
1; Figure S1 available online). The mutant exhibited similar olig-
omeric and enzymatic properties as wild-type HsMCD (Table
2). Inspection of the structure revealed both alanine-substituted
patches to be located in surface-exposed regions: Glu58-Lys59
was found in the loop connecting helices aA and aB, while the
loop containing residues 278–280, connecting strands b3 and
b4, was disordered.
Bacterial MCDs were targeted as part of the broad program of
the National Institutes of Health (NIH) Protein Structure Initiative
on structural coverage of large protein domain families (Liu et al.,
2007).We obtained crystals for several bacterial MCDs, butmost
of them showed poor diffraction quality (about 5 A˚ resolution). Af-
ter significant efforts at optimization and diffraction screening,
we collected X-ray diffraction data for RpMCD, Agrobacterium
vitis MCD (AvMCD), and Cupriavidus metallidurans MCD
(CmMCD) at up to 2.3 A˚ resolution. We solved the structure of
RpMCD by the selenomethionyl single-wavelength anomalous
diffraction method and the structures of AvMCD and CmMCD
by molecular replacement (Table 1).
Structures of MCD Monomers
The structures of the monomers of HsMCD (Figure 2A), RpMCD
(Figure 2B), AvMCD (Figure 2C), and CmMCD (Figure 2D) can be
divided into two domains: an N-terminal helical domain (130–150
residues) and a C-terminal catalytic domain (270–300 residues)
connected via a short linker peptide. Consistent with this two-
domain organization, the sequence conservation among the
MCDs also appears to be bipartite (Figure 1). For example, the
catalytic domains of HsMCD and RpMCD share 40% sequence
identity, while their helical domains have only 24% identity. The
N-terminal domain of HsMCD and several other MCDs are rich in
Leu residues, which are concentrated in the helical segments.
The helical domain contains a bundle of six helices (aA–aC,
aF–aH; Figures 2A–2D and S2). Helices aA and aB, and aG
and aH form antiparallel hairpins and are arranged somewhat
similar to those in armadillo/Huntington, elongation factor 3, pro-
tein phosphatase 2A, the yeast kinase TOR1 (HEAT), and tetratri-
copeptide repeats. However, the intervening helices aC and aF
are located away from each other and run almost perpendicular
to the other four helices. In addition, there is an insert of a helical
hairpin (aD and aE) between helices aC and aF, which projects
30 A˚ away from the rest of themonomer (Figure S1). This helical
hairpin insert as well as the helical domain itself helps mediate
the oligomerization of MCD (see below).
The catalytic domain of MCD contains a central eight-
stranded, mostly antiparallel b sheet (b1–b8) that is surrounded
by at least 11 a helices (a1–a11; Figures 2A–2D). Strands b4
and b5 in the middle of the b sheet, the only two neighboring
strands that are parallel to each other (in a b-a-b motif), are
splayed apart from each other at their C-terminal ends, and the
active site of the enzyme is located in this region (see below).
There is an insert of three additional helices (a5–a7) between
strands b5 and b6 in HsMCD, RpMCD, and AvMCD, while
CmMCD has an insert of five helices here. The sequences of
this insert are poorly conserved among the MCDs (Figure 1).
The overall structures of the catalytic domains are similar, with
root-mean-square (rms) distance of 1.2–1.5 A˚ for equivalent Ca
atoms located within 3 A˚ of each other between any pair of the
four structures. This structural similarity is particularly high for
the central b sheet of the catalytic domain, as illustrated for over-
lays between HsMCD and RpMCD (Figure 2E), HsMCD and
CmMCD (Figure 2F), and other structure pairs (Figure S1). On
the other hand, many of the helices of the catalytic domain,
especially those in the insert between b5 and b6, have large po-
sitional differences. Moreover, with the catalytic domains in
overlay, significant differences in the orientation and position of
the N-terminal helical domain are observed among the MCDs,
corresponding to relative rotations of 15–25 (Figures 2E, 2F,
and S3). In addition, the helical hairpin insert between aC and
aF is absent in CmMCD (Figures 2D and S2).
Oligomeric Architectures of MCDs
HsMCD is a tetramer in solution based on gel filtration chroma-
tography and analytical ultracentrifugation (AUC) studies
Table 1. Summary of Crystallographic Information
Structure HsMCD RpMCD AvMCD CmMCD
Space group C2221 P21212 I4122 C2
Unit cell
parameters
(a, b, c, a, b, g)
95.6, 175.3,
151.8, 90,
90, 90
141.5, 159.8,
108.6, 90,
90, 90
100.4, 100.4,
242.7, 90,
90, 90
191.0, 69.4,
74.4, 90,
103.8, 90
Resolution range
for refinement (A˚)a
30–2.8
(2.9–2.8)
30–2.7
(2.8–2.7)
30–3.1
(3.2–3.1)
30–2.3
(2.4–2.3)
Number of
observations
495,940 627,249 110,903 163,015
Rmerge (%) 12.5 (106.4) 6.0 (61.2) 10.5 (55.1) 6.3 (44.1)
Redundancy 5.0 (5.0) 4.7 (4.4) 5.2 (4.8) 3.7 (3.5)
I/sI 8.4 (1.6) 25.2 (2.4) 15.9 (2.6) 23.0 (2.7)
Number of
reflections
31,694 123,627 19,052 37,613
Completeness (%) 100 (100) 95 (85) 89 (70) 89 (72)
R factor (%) 21.2 (25.6) 22.5 (34.0) 22.0 (26.1) 23.9 (28.6)
Free R factor (%) 25.5 (29.5) 27.9 (38.3) 29.1 (34.1) 28.6 (33.3)
rms deviation in
bond lengths (A˚)
0.010 0.007 0.009 0.007
rms deviation in
bond angles ()
1.1 1.3 1.4 1.2
aThe numbers in parentheses are for the highest resolution shell.
Table 2. Summary of Kinetic Parameters on Human MCD
Enzyme Km (mM) kcat (s
1) kcat/Km (M
1s1)
Wild-type HsMCD 38 ± 12 33 ± 2 (1)a 8.7 3 105 (1)
Quintuple SER mutant 58 ± 17 45 ± 4 (0.73) 7.8 3 105 (1.1)
H423N 32 ± 4 4.7 ± 0.1 (7.0) 1.4 3 105 (6.2)
S329A 19 ± 4 0.30 ± 0.01 (110) 1.5 3 104 (58)
Y456S 132 ± 19 44 ± 2 (0.75) 3.3 3 105 (2.6)
S290F 37 ± 5 15 ± 1 (2.2) 4.1 3 105 (2.1)
aThe ratio for values between the wild-type and mutant enzymes are
given in the parentheses.
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(Figure S2), consistent with the reported oligomerization state of
many purified MCD enzymes. HsMCD sedimented in a single
peakwith an apparent molecular weight of200 kDa (Figure S2).
The HsMCD crystal structure shows that the tetramer is made of
a dimer of dimers (Figure 3A). A tight dimer of HsMCD is formed
by extensive contacts of the helical domains of the two mono-
mers, and the aD and aE helical inserts of the two monomers
interact with each other in this dimer interface. Especially, helix
aE of this insert contributes four leucine residues (122, 123,
129, and 133) to the interface. Approximately 1,800 A˚2 of the sur-
face area of each monomer is buried in the dimer. Two HsMCD
dimers then associate with each other through their catalytic do-
mains, at60 angle for the planes of the two dimers (Figure S2),
to form the tetramer with 222 symmetry. This interface primarily
involves residues at the N-terminal end of the catalytic domain,
burying 500 A˚2 of the monomer surface area.
The architecture and shape of the HsMCD tetramer were also
analyzed by electron microscopy coupled to single particle anal-
ysis. Images of negatively stained HsMCD contained a homoge-
nous population of monodispersed single particles (Figure S2).
Our three-dimensional (3D) reconstruction revealed a particle
of 125 3 100 3 100 A˚3 in size with a central cavity, consistent
in dimension and shape with the crystallographic tetramer
(Figure 3B).
RpMCD and AvMCD are also tetramers in solution, based on
multiangle static light scattering studies (data not shown). Like
HsMCD, the RpMCD (Figure 3C) and AvMCD (Figure S2) tetra-
mers are also dimer of dimers. However, the relative orientations
of the dimers are substantially different (Figure S2). The central
cavity of RpMCD tetramer also contains a helical segment (aA0)
from the N terminus of two of the monomers (Figure 3C; Supple-
mental Information).
Surprisingly, CmMCD is a dimer in solution and the crystal
structure reveals a completely different mode of dimerization
as compared to HsMCD, RpMCD, and AvMCD. The two
CmMCD monomers associate in a head-to-tail fashion such
that the N-terminal helical domain of one monomer is in contact
with the C-terminal catalytic domain of the other monomer,
including the helical insert between strands b5 and b6 (Fig-
ure 3D). Approximately 1,100 A˚2 of the surface area of each
monomer is buried in this dimer.
The variations in the oligomers of MCDs are likely due to the
differences in the conformations of the N-terminal helical do-
mains and the positions of these domains relative to the catalytic
Figure 2. Crystal Structures of MCD Monomer
Schematic drawing of the structures of HsMCD (A), RpMCD (B), AvMCD (C), andCmMCD (D). The N-terminal helical domain is shown in yellow and the C-terminal
catalytic domain in cyan. The bound position of acetyl-CoA in CurA (Gu et al., 2007) is shown as a stick model (in black). Overlays of the structures of HsMCD (in
color) and RpMCD (in gray) (E) and HsMCD (in color) and CmMCD (in gray) (F). Regions of structural difference in the catalytic domain are highlighted with the red
arrows. The difference in the orientations of the helical domains is also indicated. The structure figures were produced with PyMOL (http://www.pymol.org).
See also Figure S1.
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domains. For example, clear differences are visible between the
HsMCD and RpMCD dimers (Figure S2), thereby affecting their
tetramer formation. CmMCD lacks the helical insert in the helical
domain and has two additional helices between b5 and b6 in the
catalytic domain (Figure 2D), which may explain why it cannot
form a similar dimer and tetramer as HsMCD or RpMCD.
While this paper was under review, a structure of HsMCD at
3.29 A˚ resolution was reported (Aparicio et al., 2013). The overall
structures of the HsMCD monomers in the two reports are
similar, with rms distance of 1.5 A˚ for 380 equivalent Ca atoms
(Figure S2). There are recognizable differences in the organiza-
tion of the dimer and tetramer between the two structures,
although the overall architectures of the two tetramers are similar
(Figure S2).
Unexpected Structural Homology to GNAT Enzymes
The structure of the MCD catalytic domain unexpectedly shows
strong homology to proteins belonging to the GNAT superfamily
(Dyda et al., 2000; Neuwald and Landsman, 1997; Vetting et al.,
2005), based on a Protein Data Bank (PDB) search with the pro-
gram DaliLite (Holm et al., 2008). As the name indicates, most of
these enzymes are N-acetyltransferases, a catalytic activity
highly distinct from that of MCD. On the other hand, the overall
backbone folds of these enzymes are homologous. GNAT pro-
teins typically contain a seven-stranded b sheet, which corre-
Figure 3. The Oligomers of MCD
(A) Structure of the HsMCD tetramer. A semi-
transparent surface of the structure is also shown.
(B) Docking of the HsMCD tetramer structure into
the EM reconstruction.
(C) Structure of the RpMCD tetramer.
(D) Structure of the CmMCD dimer. The 2-fold axis
of the dimer is indicated with the oval (black).
See also Figure S2.
sponds to the first seven strands in the
catalytic domain of MCD, with the splay-
ing of the b4 and b5 strands a common
feature among these structures. The
sequence conservation between MCDs
and these other GNAT members is, how-
ever, much lower, around 10% for struc-
turally equivalent residues. As expected,
the catalytic machinery in the active site
is also distinct between MCD and the N-
acetyltransferases.
The closest structural homolog, with a
Z score of 16.6 from DaliLite, is the cata-
lytic domain of the loading module of the
polyketide synthase for curacin A (CurA)
from Lyngbya majuscula, a GNAT protein
that was shown not to have N-acetyl-
transferase activity (Gu et al., 2007; Fig-
ures 4A and 4B). Instead, this loading
module harbors both malonyl-CoA
decarboxylase and acetyl S-transferase
activities. Despite the 13% identity for
structurally equivalent residues between
the two proteins, the catalytic residues for the decarboxylase ac-
tivity of CurA are conserved in MCD (see below).
The N-terminal helical domain of MCDs does not have a coun-
terpart in the GNAT enzymes. Consequently, the modes of olig-
omerization of MCDs are entirely different from these other
GNAT enzymes. GNATs typically exist as monomers or dimerize
via their GNAT core, and the predominant dimerization mode is
by juxtaposing the GNAT b strands from both subunits to form
a continuous b sheet. In contrast, the GNAT b strands in MCDs
are not available for dimerization due to the presence of the large
helical insert between strand b5 and b6. MCD dimerization is
instead mediated by the N-terminal helical domain.
MCD represents a second example where a GNAT protein
possesses a catalytic activity distinct from N-acetyltransferase.
At the same time, the different activities of these GNAT proteins
share the common substrate of acetyl- or malonyl-CoA. There-
fore, the GNAT scaffold may have evolved to recognize the
CoA moiety, and substitutions of several critical residues in the
catalytic machinery may be sufficient to change the catalytic ac-
tivity or substrate preference, such as succinyl-CoA (see below)
(Vetting et al., 2008).
The Active Site of MCD
Our extensive efforts to cocrystallize MCD with malonyl-CoA or
acetyl-CoA have not been successful. Therefore, the structure
Structure
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of acetyl-CoA bound to CurA (Gu et al., 2007) was used as a
guide for analyzing the MCD active site. This binding mode of
acetyl-CoA is also generally similar to that in canonical GNAT en-
zymes, suggesting that the binding mode to MCD is likely to be
similar as well.
The active site of MCD is located in a prominent groove in the
surface of the monomer, where the most conserved residues
among these enzymes are located (Figure 5A). The other mono-
mers of the MCD oligomer make little, if any, contribution to the
active site. For RpMCD, residues 55–58 in the other monomer of
the dimer, in the loop linking the first two helices of theN-terminal
domain, approach within 10 A˚ of the expected position of the
adenosine group in the active site. The equivalent loop in HsMCD
is much longer, and Ala58 in this loop could have direct interac-
tions with the adenine base of CoA. In the CmMCD dimer, the
second monomer is located 20 A˚ away from the active site.
The pantotheine group of CoA is positioned along strand b4
(Figures 5B and S3). The diphosphate and adenosine groups
interact with the loop linking this strand to the following helix
(a4) in HsMCD, and the diphosphate group also has favorable in-
teractions with the dipole of this helix. In fact, this loop contains
the signature sequence motif A in canonical GNAT enzymes
(Neuwald and Landsman, 1997), (Q/R)xxGx(G/A)xxL, but the
motif is not fully conserved in MCD, 299-(Q/R/A)xxxx(G/A)xxL-
307 (Figure 1). Moreover, the loop and the following helix a4
are positioned differently in RpMCD (Figures 4 and S3) and
CmMCD (Figure S1), suggesting that the binding mode of CoA
to these MCDs may be somewhat different unless there is a
conformational change upon CoA binding in these two enzymes.
The 30 phosphate group on the ribose of CoA is recognized by
Arg387 in CurA (equivalent to Asn421 in HsMCD; Figure 5B).
This residue is equivalent to Arg387 in RpMCD, which may
have a similar function. However, this Arg residue is not
conserved among the MCD enzymes. It shows variations to
Asn in animal MCDs and His in some bacterial MCDs (Figure 1).
The acetyl group of acetyl-CoA interacts with conserved resi-
dues His389 and Thr355 in CurA (Figure 5B), which is proposed
to be the catalytic dyad for its malonyl-CoA decarboxylase activ-
ity (Gu et al., 2007). The H389A, H389N, and T355Vmutants have
drastically reduced decarboxylase activity. The equivalent resi-
dues, His423 and Ser329 in HsMCD and His389 and Ser312
in RpMCD, are strictly conserved among the MCDs (Figure 1).
In comparison, the His residue is equivalent to a Tyr residue in
the canonical GNAT enzymes, which serves as the general
acid for catalysis (Dyda et al., 2000; Neuwald and Landsman,
1997; Vetting et al., 2005). On the other hand, the Thr/Ser residue
of CurA/MCD is not conserved in the canonical GNAT enzymes,
while the general base for these enzymes, a Glu residue, is not
conserved in CurA/MCD. These differences in the catalytic resi-
dues are likely the molecular basis for the distinct activity of
CurA/MCD compared to the canonical GNATs.
The imidazole ring of His389 in CurA is held in place through a
hydrogen bond with Tyr419. The equivalent residue in HsMCD,
Tyr456, is also conserved among the MCDs. The carboxylate
group of the malonyl-CoA substrate may lie over the surface of
Phe288 in strand b4 (Figure 5B; HsMCD numbering), which is
another strictly conserved residue among the MCDs (Figure 1).
Themain chain of Thr355 in CurA has interactions with Arg404.
However, this Arg residue is not conserved in RpMCD (Asp404),
and in fact, an Asp residue is conserved at this position among
the MCDs. The Arg404 residue may also be important for the
acetyl S-transferase activity of CurA (Gu et al., 2007). The
absence of this residue in MCD may be consistent with its lack
of S-transferase activity.
Acetylation of Lys210, as well as mutation of Lys210 to Met,
has been reported to inactivate rat MCD (Nam et al., 2006). Bind-
ing of acetyl-CoA protects rat MCD from the acetylation. In the
HsMCD structure, the equivalent Lys211 side chain is on the sur-
face of the tetramer, in a helix (a1) connecting strands b1 and b2,
and20 A˚ from the active site. This side chain is mostly exposed
to the solvent and does not have interactions with other
conserved residues. Thus, it is not clear why this residue is
essential for the catalysis by rat MCD.
To assess the functional importance of the active site His-Ser/
Thr dyad of MCD, we carried out mutagenesis and kinetic
studies with HsMCD. The S329A mutant of HsMCD had a 110-
fold loss in kcat and 58-fold loss in kcat/Km, and the H423Nmutant
had a 7-fold loss in kcat (Table 2), consistent with their important
roles in catalysis. In silico docking of malonyl-CoA into the
HsMCD active site supports the kinetic data, showing that
the substrate can position its thioester carbonyl (bridging the
carboxylate leaving group and CoA backbone) in the vicinity
(3.2 A˚) of Ser329 and His423 (Figure S3).
The reaction mechanism for MCD bears similarity to the acetyl
transfer reaction of canonical GNATs, as they all need to polarize
and stabilize the developing negative charge on the thioester
carbonyl group (Figure 5C). Using HsMCD as example, we
postulate that MCD proceeds through the formation of the tauto-
merized enolate intermediate, with the Ser329 and His423 dyad
adopting important catalytic roles consistent with our docking
and kinetic analysis. Phe288 may provide a nonpolar environ-
ment for the CO2 leaving group, and the carbanion can abstract
the proton from the side chain hydroxyl group of Ser329 acting
as an acid (Figure 5C). This mechanism also has resemblance
to that of a number of other CoA decarboxylases that do not
employ cofactors (such as pyridoxal phosphate, thiamine, or
Figure 4. Structural Conservation with CurA
(A) Overlay of the structures of HsMCD (in color) and CurA (in gray). Acetyl-CoA
in the CurA complex is shown as a stick model (black).
(B) Overlay of the structures of RpMCD (in color) and CurA (in gray). The red
asterisk indicates large conformational differences in the N-terminal region of
helix a4 between the two structures, which interacts with the phosphate
groups of CoA in CurA.
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metal ions) to delocalize the buildup of the negative charge (Fu
et al., 2004).
Molecular Basis of Disease-Causing Mutations in MCD
The structure of HsMCD provides a molecular framework for un-
derstanding the impact of loss-of-function alleles in hereditary
MCD deficiency. While the nonsense, frameshift, and deletion
mutations result in truncated and thus nonfunctional proteins,
the 11 known missense mutations (Table S1) are distributed
throughout the structure with no discernible hot spot regions
(Figure 6). The potential structural and biochemical conse-
quences of these substitutions can be classified into three types.
The first type is protein mistargeting and includes the two most
N-terminal mutations, G3D and M40T, each of which lies within
the predicted mitochondrial targeting sequence. Both mutations
have been demonstrated to affect protein localization (Wightman
et al., 2003). The second type of substitution likely disrupts pro-
tein folding through either protein instability or aggregation.
These include A69V and L161P in the N-terminal helical domain,
as well asW384C, S440I, and S477F in the catalytic domain. The
third type involves substitutions in the GNAT core, affecting res-
idues highly conserved among MCDs. These include S290F,
G300V, L307R, and Y456S (Figure 6). Ser290 is located in strand
b4 near the binding site for the CoA pantotheine moiety, though
facing away from it. Mutation to the larger Phe residue would be
expected to result in clashes with neighboring amino acids
(His254 and Tyr289) and, hence, possible rearrangement of the
Figure 5. The Active Site of MCD
(A) Molecular surface of HsMCD in the active
site region, colored by sequence conservation
(magenta, most conserved; cyan, least
conserved). The bound position of acetyl-CoA in
CurA (Gu et al., 2007) is shown as a stick model (in
black).
(B) An overlay of HsMCD (in color) and CurA (in
gray) in the active site region. Side chains in
HsMCD are labeled. The catalytic residues His423
and Ser329 of HsMCD are equivalent to His389
and Thr335 of CurA. Please see Figure S3 for a
stereo version of this panel.
(C) Proposed catalytic mechanism for MCD
(HsMCD numbering). Interatomic distance be-
tween His423 imidazole nitrogen and Ser329 hy-
droxyl oxygen is denoted in black line. Question
mark represents possible proton transfer to re-
protonate Ser329, from His423, a water molecule,
or other unidentified sources.
See also Figure S3.
active site and a partial loss of function.
Indeed, the reconstituted S290F mutant
showed a 2-fold decrease in kcat in vitro
(Table 2). Gly300 and Leu307 are in the
loop linking b4 and the following helix
a4, being part of motif A. Both mutations
result in substitution to larger residues
that may clash with surrounding residues
within this loop as well as residues on
strand b3. Finally, Tyr456 interacts with
the catalytic His423 residue (Figure 5C).
Mutation to Ser would be expected to result in loss of His423 sta-
bilization with consequent decreased substrate stability. In vitro,
the Y456S mutant showed a 3.5-fold increased Km (Table 2),
consistent with this proposal.
In summary, we report here structural information on MCD,
revealing its catalytic machinery, oligomer organization, mecha-
nism of disease-causing mutations, as well as unexpected ho-
mology to GNAT enzymes. The structural information should
also facilitate the design and optimization of inhibitors against
this enzyme. It has been suggested that the current inhibitors
may require a hydrogen bond to a histidine residue for binding
(Cheng et al., 2006c), and our structure suggests that this very
likely is the catalytic His423 residue. Therefore, the active site
of MCD is a promising target for the development of new thera-
peutic agents against human diseases.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
A DNA fragment containing HsMCD (amino acids [aa] 40–491; IMAGE clone:
3357140) was subcloned into the pNIC28-Bsa4 vector (GenBank accession
no. EF198106), incorporating an N-terminal tobacco etch virus (TEV)-cleav-
able His6-tag. For surface entropy reduction, residues Glu58-Lys59 and
Glu278-Glu279-Lys280 were replaced with Ala. The expression plasmids
were transformed into E. coli BL21(DE3)-R3-pRARE2 cells, grown in Terrific
broth medium with induction by 0.1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG) overnight at 18C. Proteinwas purified by affinity (Ni-nitrilotriacetic acid;
QIAGEN) and gel filtration (Superdex 200; GE Healthcare) chromatography.
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The production of the three bacterial MCDs, Rmet_2797 (CmMCD),
RPA0560 (RpMCD), and Avi_5372 (AvMCD) from Cupriavidus metallidurans,
Rhodopseudomonas palustris, and Agrobacterium vitis, respectively, was car-
ried out as part of the high-throughput protein production process of the
Northeast Structural Genomics Consortium (NESG) (Acton et al., 2005). The
CmMCD, RpMCD, and AvMCD proteins correspond to NESG targets
CrR76, RpR127, and RiR35, respectively. Full-length RpMCD and AvMCD
were cloned into a pET21d (Novagen) derivative with C-terminal His-tag.
Full-length CmMCD was cloned into pET26b with a C-terminal His-tag.
Escherichia coli BL21 (DE3) pMGK cells, a rare codon enhanced strain, were
transformed with each plasmid. A single isolate was transferred to 500 ml of
Luria broth with ampicillin and kanamycin and incubated for 6 hr at 37C.
This preculture (40 ml) is then used to inoculate a 250 ml flask containing
40 ml of MJ9 minimal media (Jansson et al., 1996) and incubated overnight
at 37C. The entire volume of overnight culture is then used to inoculate a 2 l
baffled flask containing 1.0 l of MJ9. The cultures are incubated at 37C until
the optical density at 600 nm reaches 0.8–1.0 units, equilibrated to 17C,
and induced with IPTG (1 mM final concentration) after addition of several
amino acids to the medium to downregulate methionine synthesis (lysine,
phenylalanine, and threonine at 100 mg/l; isoleucine, leucine, and valine at
50 mg/l; and L-selenomethionine at 60 mg/l) for 15 min (Doublie´ et al., 1996).
In the case of CmMCD, the media contained methionine instead. Following
overnight incubation, the cells were harvested by centrifugation. However,
the full-length CmMCD, RpMCD, and AvMCD could not be purified this way,
due to low expression and/or low solubility. Subsequently, construct optimiza-
tion experiments revealed that expression of RpMCD, AvMCD, and CmMCD
construct containing residues 8–451, 1–448, and 57–473, respectively, yielded
soluble protein in each case without noticeable protein aggregation. The pET
expression vectors for these constructs (NESG RpR127-8-451-21.13, NESG
RiR35-1-448-21.13, and NESG ReR178-25-448-28) have been deposited in
the Protein Structure Initiative Materials Repository (http://psimr.asu.edu).
Selenomethionyl RpMCD, AvMCD, and native CmMCD were purified by
standard methods. Cell pellets were resuspended in lysis buffer (50 mM Tris
[pH 7.5], 500 mM NaCl, 40 mM imidazole, and 1 mM Tris-(2-carboxyethyl)
phosphine) and disrupted by sonication. The resulting lysate was clarified by
centrifugation at 26,0003 g for 45 min at 4C. The supernatant is then loaded
onto an A¨KTAxpress system (GE Healthcare), and a two-step automated pu-
rification protocol is performed, comprised of a Ni-affinity column (HisTrap
HP, 5 ml) and a gel filtration column (Superdex 75 26/60, GE Healthcare) in a
linear series. A buffer containing 10 mM Tris (pH 7.5), 100 mM NaCl, 5 mM di-
thiothreitol (DTT), and 0.02% (w/v) NaN3 is used for gel filtration. The purified
Se-Met labeled RpMCD, AvMCD, and native CmMCD were concentrated to
11, 8, and 10 mg/ml, respectively, flash frozen in aliquots, and used for crys-
tallization screening. Sample purity (>95%) andmolecular weight were verified
by SDS-PAGE and MALDI-TOF mass spectrometry, respectively.
Protein Crystallization
Purified HsMCD (SER quintuple mutant) was concentrated to 10 mg/ml in a
buffer containing 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) (pH 7.5), 100 mM NaCl, 1% (v/v) glycerol,l and 5 mM decanoyl-CoA.
Crystals were obtained by sitting-drop vapor diffusion at room temperature
by incubating protein in a 2:1 ratio with a precipitant containing 10% (w/v) poly-
ethylene glycol (PEG) 20,000 and 0.1 M 2-(N-morpholino)ethanesulfonic acid
(pH 6.0). The crystals belong to space group C2221, with a dimer of HsMCD
in the asymmetric unit. The tetramer is generated through a crystallographic
2-fold axis.
The purified Se-Met-labeled RpMCD, AvMCD, and native CmMCD were
crystallized using microbatch method at 18C. In the case of RpMCD and
AvMCD, 2 ml of the protein solution containing 10 mM Tris (pH 7.5), 100 mM
NaCl, 5 mM DTT, and 0.02% NaN3 were mixed with 2 ml of the precipitant so-
lution consisting of 0.1 M magnesium nitrate, 100 mM Tris (pH 8.5), and 33%
(v/v) PEG 400 for RpMCD and 200 mM ammonium sulfate and 20% (w/v)
PEG3350 for AvMCD. For CmMCD, 2 ml of the protein in a buffer consisting
of 20 mM Tris (pH 7), 250 mM NaCl, 5% (v/v) glycerol, and 3 mM malonyl-
CoA were mixed with a crystallization cocktail containing 160 mMmagnesium
chloride, 80mMTris (pH 8.5), 24% (w/v) PEG 4000, 20% (v/v) glycerol, and 3%
(v/v) ethanol. The RpMCD and AvMCD crystals were cryoprotected by supple-
menting their respective crystallization cocktail with 20% (v/v) ethylene glycol
and 20% (v/v) glycerol, respectively. No cryoprotecting solution was added
into the crystallization cocktail containing CmMCD crystals for data collection
at 100 K.
Crystals of RpMCD, AvMCD, and CmMCD belong to space group P21212,
I4122 and C2, respectively, with four, one, and two molecules in the crystallo-
graphic asymmetric unit.
Structure Determination and Refinement
For HsMCD, the structure was solved by multiple isomorphous replacement
with anomalous scattering phasing. HsMCD crystals were derivatized with
thimerosal or K2PtCl4 by 20 min incubation in reservoir solution supplemented
with 5mMof the respective heavy atom compound. X-ray diffraction datawere
collected at the Diamond Light Source beamlines IO2 and IO3 and processed
and scaled with XDS (Kabsch, 2010) and Scala (Collaborative Computational
Project, 1994), respectively. SHELXD (Sheldrick, 2008) identified three heavy
atom sites in the mercury derivative. After including both derivatives in SHARP
(Vonrhein et al., 2007) and subsequent density modification with SOLOMON
(Abrahams and Leslie, 1996), substantial parts of themodel were automatically
built withBUCANEER (Cowtan, 2006).Manualmodel rebuildingwascarriedout
with Coot (Emsley and Cowtan, 2004) and structure refinement with BUSTER
(Global Phasing). No ligand electron density was observed in the active site.
Residues 60–65, 115 and 116, 276–281, and 344–371, which represent sur-
face-exposed regions in the structure, are disordered and not modeled.
The structure of RpMCDwas determined by a single-wavelength anomalous
diffraction data set to resolution 3.1 A˚, whichwas collected at the peak absorp-
tion wavelength of selenium at the X6A beamline of the National Synchrotron
Light Source. The diffraction images were processed with the HKL package
(Otwinowski and Minor, 1997), and the selenium sites were located with the
program SHELX (Sheldrick, 2008). SOLVE/RESOLVE was used for phasing
the reflections and automated model building (Terwilliger, 2003). The majority
of the model was built manually with the program XtalView (McRee, 1999). The
structure refinement was performed with CNS 1.3 (Bru¨nger et al., 1998).
The model thus obtained for RpMCD was used as a search model for struc-
ture determination of another data set of RpMCD to resolution 2.7 A˚. The
Figure 6. Molecular Basis for MCD Disease-Causing Mutations
The 11 missense pathogenic mutations (in red for those that could affect
catalysis/substrate binding and blue for those that could affect folding/sta-
bility) are mapped onto the structure of HsMCD.
See also Table S1.
Structure
Crystal Structures of Malonyl-CoA Decarboxylase
Structure 21, 1182–1192, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1189
model was subsequently used to determine structures of CmMCD and
AvMCD to resolution 2.3 A˚ and 3.1 A˚, respectively, using the molecular
replacement method implemented in the program Molrep (Vagin and Teplya-
kov, 2000). The data processing and refinement statistics are summarized in
Table 1.
Decarboxylase Activity Measurement
MCD catalytic activity was determined following a published protocol (Kolat-
tukudy et al., 1981). For HsMCD, the following reagents were added to a total
of 100 ml in a 96 well plate: 50mMHEPES (pH 7.5), 1mMdithiothreitol, 5mML-
malate, 1 mM nicotinamide adenine dinucleotide (NAD)+, 0.1 mM reduced
NAD, 1.925 U malate dehydrogenase (Sigma-Aldrich), 0.4 U citrate synthase
(Sigma-Aldrich), 100-1000 nM HsMCD protein, and various concentrations
(0 mM–500 mM) of malonyl-CoA. Absorbance changes at 340 nm were
measured for 30min and linear velocity used to calculate enzyme activity using
GraphPad Prism (v.5.01).
Analytical Ultracentrifugation
Sedimentation velocity (SV) experiments were performed in a Beckman Op-
tima XL-I analytical ultracentrifuge (Beckman Instruments) using AnTi-50 rotor.
Experiments were conducted at 30,000 rpm and 4C using absorbance detec-
tion and cells loaded with 50 mM HsMCD in 10 mM HEPES (pH 7.5) and
150 mM NaCl. SV data were analyzed using SEDFIT (Schuck, 2000), while
sedimentation coefficients, s, were calculated with SEDNTERP (Laue et al.,
1992) version 1.09.
Analytical Gel Filtration
Analytical gel filtration was performed on a Superdex 200 HiLoad 10/30 col-
umn (GE Healthcare) pre-equilibrated with 10 mM HEPES (pH 7.5) and
150 mM NaCl at a flow rate of 0.3 ml/min.
Electron Microscopy
We studied the HsMCD assembly by negative staining electron microscopy
and single particle analysis. Data were collected on a FEI F20 field emission
gun microscope, equipped with an 8k 3 8k charge-coupled device camera.
Images were collected under low dose mode at a magnification of 50,000X
at a final sampling of 1.6 A˚/pixel at the specimen level. Single particle images
were selected interactively using the Boxer program from the EMAN package
(Ludtke et al., 1999). Image processing was performed using the IMAGIC-5
package (van Heel et al., 1996), and the single particle images were analyzed
by multivariate statistical analysis. Selected class averages were used to
calculate a starting 3D volume by common lines using the Euler program in
the IMAGIC-5 package with no symmetry imposed. Manual fitting of the
HsMCD tetramer was performed with UCSF Chimera (Goddard et al., 2007).
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